Answers are grounded in this paper and cite their sources.
// David J. Duffy 1, 7, * , Aleksandar Krstic 1, * , Thomas Schwarzl 1, 8 , Melinda Halasz 1 , Kristiina Iljin 6 , Dirk Fey 1 , Bridget Haley 1 , Jenny Whilde 1 , Saija Haapa-Paananen 6 , Vidal Fey 6 , Matthias Fischer 5 , Frank Westermann 4 , Kai-Oliver Henrich 4 , Steffen Bannert 4 , Desmond G. Higgins 1, 2, 3 , Walter Kolch 1, 2, 3 1 Systems Biology Ireland, University College Dublin, Belfield, Dublin, Ireland 2 Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin, Ireland 3 School of Medicine, University College Dublin, Belfield, Dublin, Ireland 4 Division of NB Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany 5 Department of Paediatric Haematology and Oncology and Center for Molecular Medicine Cologne (CMMC), University Hospital Cologne, Cologne, Germany 6 VTT Technical Research Centre of Finland, Espoo, Finland 7 Current address: The Whitney Laboratory for Marine Bioscience, University of Florida, St. Augustine, Florida, USA 8 Current address: European Molecular Biology Laboratory (EMBL), Heidelberg, Germany * These authors contributed equally to this work Correspondence to: David J. Duffy, email: david.duffy@ucd.ie Keywords: neuroblastoma, melanoma, colorectal cancer, MYC (c-MYC), mRNA sequencing (mRNA-seq) Received: November 03, 2015 Accepted: July 26, 2016 Published: August 11, 2016 ABSTRACT Wnt signalling is involved in the formation, metastasis and relapse of a wide array of cancers. However, there is ongoing debate as to whether activation or inhibition of the pathway holds the most promise as a therapeutic treatment for cancer, with conflicting evidence from a variety of tumour types. We show that Wnt/β-catenin signalling is a bi-directional vulnerability of neuroblastoma, malignant melanoma and colorectal cancer, with hyper-activation or repression of the pathway both representing a promising therapeutic strategy, even within the same cancer type. Hyper-activation directs cancer cells to undergo apoptosis, even in cells oncogenically driven by β-catenin. Wnt inhibition blocks proliferation of cancer cells and promotes neuroblastoma differentiation. Wnt and retinoic acid co-treatments synergise, representing a promising combination treatment for MYCN-amplified neuroblastoma. Additionally, we report novel cross-talks between MYCN and β-catenin signalling, which repress normal β-catenin mediated transcriptional regulation. A β-catenin target gene signature could predict patient outcome, as could the expression level of its DNA binding partners, the TCF/LEFs. This β-catenin signature provides a tool to identify neuroblastoma patients likely to benefit from Wnt-directed therapy. Taken together, we show that Wnt/β-catenin signalling is a bi-directional vulnerability of a number of cancer entities, and potentially a more broadly conserved feature of malignant cells.
No takes yet. Share an insight, caveat, or question.
Duffy et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: